Stifel lifts ORIC Pharmaceuticals price target to $18 on positive ESMO data

Stifel raised its price target for ORIC Pharmaceuticals to $18 from $14 while keeping a Buy rating. The adjustment follows encouraging Phase 1b enozertinib data and reduced risk perception for the MEVPRO‑1 trial presented at ESMO. The stock is trading at $13.17, up 61% year‑to‑date. Other analysts also raised targets, citing pipeline progress.

Stifel’s new $18 target implies about 36.7% upside from the recent close, which may attract buying interest. The higher target reflects analyst confidence in upcoming data, potentially supporting the stock’s momentum.

  • 1Stifel increased its price target to $18 from $14.
  • 2The current share price is $13.17.
  • 3ORIC is up 61% year‑to‑date.
  • 4Stifel maintained a Buy rating.
  • 5The price target is based on positive Phase 1b enozertinib data and reduced risk for the MEVPRO‑1 trial presented at ESMO.

Sources